FINWIRES · TerminalLIVE
FINWIRES

$GSK

57 stories mentioning GSKUpdated 5d ago

Every FINWIRES story that references GSK, newest first.

What's the latest news on GSK?

Sectors

Sector Update: Healthcare Stocks Fall Late Afternoon

Healthcare stocks declined late Tuesday afternoon with the NYSE Healthcare Index falling 2.5% and the State Street Health Care Select Sector SPDR ETF (XLV) dropping 2.2%.The iShares Biotechnology ETF (IBB) shed 1.9%.In corporate news, Boston Scientific (BSX) flagged its inability to meet its near-term financial outlooks amid a "material impact" from a recent cybersecurity incident. Boston Scientific shares were down 5%.Novartis (NVS) shares fell past 13% after it said a phase 3 trial assessing delpacibart etedesiran in people with myotonic dystrophy type 1 failed to meet its primary endpoint.GSK (GSK) is raising $6.5 billion from a US high-grade debt sale to help refinance bridge funding for its $10.6 billion takeover of Nuvalent, Bloomberg reported. GSK shares fell 2.4%.Novo Nordisk (NVO) has stopped two additional trials of its experimental cardiovascular drug, ziltivekimab, after an independent committee found a low chance they would produce a different result from an earlier failed study, Reuters reported. The trials, which tested the drug in heart failure patients, will end early, the company told. It added that patients will continue through to their 3-months follow-up as already planned. Novo shares were shedding 2.7%.

$BSX$GSK$NVO$NVS
Sectors

Sector Update: Healthcare

Healthcare stocks declined late Tuesday afternoon with the NYSE Healthcare Index falling 2.5% and the State Street Health Care Select Sector SPDR ETF (XLV) dropping 2.2%.The iShares Biotechnology ETF (IBB) shed 1.8%.In corporate news, GSK (GSK) is raising $6.5 billion from a US high-grade debt sale to help refinance bridge funding for its $10.6 billion takeover of Nuvalent, Bloomberg reported. GSK shares fell 2.5%.

$GSK
Wire

Market Chatter: GSK to Raise $6.5 Billion From US Debt Sale to Fund Nuvalent Acquisition

GSK (GSK) is raising $6.5 billion from a US high-grade debt sale to help refinance bridge funding for its $10.6 billion takeover of Nuvalent, Bloomberg reported, citing people familiar with the matter.The size of the bond sale is about $500 million more than initial talks, the people reportedly told Bloomberg.GSK didn't immediately reply to a request for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $48.69, Change: $-1.21, Percent Change: -2.42%

$GSK
Wire

GSK to Raise $6.5 Billion From US Debt Sale to Fund Nuvalent Acquisition, Bloomberg Reports

GSK to Raise $6.5 Billion From US Debt Sale to Fund Nuvalent Acquisition, Bloomberg Reports

$GSK
Sectors

Sector Update: Healthcare Stocks Higher Thursday Afternoon

Healthcare stocks were slightly higher Thursday afternoon, with the NYSE Healthcare Index increasing 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.1%.The iShares Biotechnology ETF (IBB) eased 0.3%.In corporate news, Hutchmed (HCM) shares jumped 17% after the company said its unit licensed rights to GSK (GSK) to develop and commercialize experimental cancer treatment HMPL-A830 outside greater China. GSK shares added 0.8%.AbbVie (ABBV) said Thursday that it has completed its acquisition of Apogee Therapeutics (APGE), valuing the clinical-stage biotechnology company at about $10.9 billion, or $135.11 per share. AbbVie shares were down 0.3%.Ultragenyx Pharmaceutical (RARE) shares fell 45% after the firm said a phase 3 study of apazunersen in Angelman syndrome did not achieve the primary endpoint nor a key secondary endpoint.

$ABBV$GSK$HCM$RARE
Wire

Market Chatter: Haleon Negotiates Better Shelf Placement at Walmart, Target

Haleon (HLN) has negotiated better shelf placement at Walmart (WMT) and Target (TGT), Reuters reported Thursday.Haleon was demerged from GlaxoSmithKline (GSK) in 2022.The company said it has offered major retailers better prices and promotions, as well as exclusivity on new products, in exchange for more prominent shelf space.Haleon, Target, and Walmart did not immediately respond to requests for comment from.Shares of Haleon were down 2%.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $9.76, Change: $-0.16, Percent Change: -1.61%

$GSK$HLN$TGT$WMT
Sectors

Sector Update: Healthcare Stocks Edge Higher Pre-Bell Thursday

Healthcare stocks were edging higher pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) advancing by 0.5%.Hutchmed (HCM) shares were up more than 11% after the company said its unit licensed rights to GSK (GSK) to develop and commercialize experimental cancer treatment HMPL-A830 outside greater China.Ultragenyx Pharmaceutical (RARE) shares were down more than 46% after the company said its phase 3 study of apazunersen in Angelman syndrome failed to achieve the primary endpoint or a key secondary endpoint.Liquidia (LQDA) was up more than 1% after the company said the US Food and Drug Administration has granted fast-track designation to Yutrepia inhalation powder to treat Raynaud's phenomenon associated with systemic sclerosis.

$GSK$HCM$IBB$LQDA$RARE$XLV
Sectors

Sector Update: Healthcare

Healthcare stocks were edging higher pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.2% and the iShares Biotechnology ETF (IBB) advancing by 0.5%.Hutchmed (HCM) shares were up more than 12% after the company said its unit licensed rights to GSK (GSK) to develop and commercialize experimental cancer treatment HMPL-A830 outside Greater China.

$GSK$HCM
Wire

Hutchmed Signs Cancer Treatment Licensing Agreement With GSK; Shares Rise Pre-Bell

Hutchmed (HCM) said Thursday its unit licensed rights to GSK (GSK) to develop and commercialize experimental cancer treatment HMPL-A830 outside Greater China.The agreement includes a $110 million upfront fee alongside prospective milestone payments of up to roughly $1.19 billion, the company said.The therapy targets KRAS-altered solid tumors in colorectal, pancreatic and lung cancers, and the company will execute the phase 1 clinical trial starting in H2 before GSK assumes future development and sales.Shares of Hutchmed rose more than 16% in Thursday's premarket activity.Price: $14.01, Change: $+1.97, Percent Change: +16.36%

$GSK$HCM
Asia Markets

European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading

European equities traded in the US as American depositary receipts were trending lower late Thursday morning, declining 0.58% to 1,962.65 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by 3D printer company Materialise (MTLS) and software firm, SAP (SAP), which rose 4.6% and 3% respectively. They were followed by biopharmaceutical company Cellectis (CLLS) and semiconductor company Sequans Communications (SQNS), which were up 2.9% and 2.1% respectively.The decliners from continental Europe were led by pharmaceutical companies Novo Nordisk (NVO) and Sanofi (SNY), which lost 2.8% and 1.3% respectively. They were followed by biotech firm BioNTech (BNTX) and consumer goods company Unilever (UL), which dropped 1.2% and 1.1% respectively.The gainers from the UK were led by biotech firm Trinity Biotech (TRIB) and software company Endava (DAVA), which advanced 5.1% and 4.1% respectively. They were followed by biotech company Autolus Therapeutics (AUTL) and educational publisher Pearson (PSO), which increased 1.1% and 0.9% respectively.The decliners from the UK and Ireland were led by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and Akari Therapeutics (AKTX), which fell 6.9% and 3% respectively. They were followed by biopharmaceutical company NuCana (NCNA) and pharmaceutical company GSK (GSK), which were down 2.6% and 1.9% respectively.

$AKTX$AUTL$BDRX$BNTX$CLLS$DAVA$GSK$MTLS$NCNA$NVO$PSO$SAP$SNY$SQNS$TRIB$UL
Wire

GSK's ViiV Healthcare Says US FDA Approves Tivicay PD for Pediatric HIV Patients

GSK's (GSK) majority-owned ViiV Healthcare unit said Wednesday the US Food and Drug Administration has approved Tivicay PD, or dolutegravir, for use with other antiretroviral medicines to treat HIV-1 infection in children weighing at least 2 kilograms, including eligible newborns.The approval covers treatment-naive or treatment-experienced patients who have not previously received an integrase strand transfer inhibitor, ViiV Healthcare said.The approval is supported by data that showed dolutegravir reached therapeutic drug levels with a safety profile consistent with that seen in older pediatric and adult patients, the company said.Price: $51.80, Change: $-0.27, Percent Change: -0.52%

$GSK
Commodities

Exchange-Traded Funds, Equity Futures Fall Pre-Bell Monday as Investors Await Details on US Sanctions Against Iran

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.2% and the actively traded Invesco QQQ Trust (QQQ) was 0.6% higher in Monday's premarket activity as investors await details of US President Donald Trump's planned sanctions on Iran.US stock futures were also lower, with S&P 500 Index futures down 0.2%, Dow Jones Industrial Average futures slipping 0.1%, and Nasdaq futures retreating 0.5% before the start of regular trading.In premarket activity, bitcoin was up by 1.1%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 1.3% higher, Ether ETF (EETH) advanced 3.1%, and Bitcoin & Ether Market Cap Weight ETF (BETH) gained 2.3%.The Chicago Federal Reserve Bank's monthly National Activity Index fell to a reading of negative 0.08 in July from 0.06 in June, compared with expectations for a smaller decrease to negative 0.05 in a Bloomberg survey.Power Play:TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) retreated 0.9%, the iShares US Technology ETF (IYW) was 0.5% lower, and the iShares Expanded Tech Sector ETF (IGM) was down 0.6%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) declined 1.3% while the iShares Semiconductor ETF (SOXX) fell 1.6%.Parsons (PSN) shares were up nearly 2% after the company said it received a $514 million contract option from the United States Department of Defense's Missile Defense Agency to provide engineering and technical support.Winners and Losers:ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.5%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was 0.1% higher, and the iShares US Consumer Staples ETF (IYK) was 0.4% lower. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) gained 0.1%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) was down 1.1%%.Alibaba Group (BABA) shares were down more than 2% pre-bell a day after the company priced a placement of 710 million new shares at 112.70 Hong Kong dollars ($14.38) apiece in Hong Kong for about HK$80 billion in proceeds.Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.3%, the Vanguard Health Care Index Fund (VHT) was up 0.4%, while the iShares US Healthcare ETF (IYH) fell 3%. The iShares Biotechnology ETF (IBB) gained 0.3%.GSK's (GSK) stock was down 1% despite the company announcing positive regulatory updates, including approval for Hibsago in Japan and a priority review for Jemperli in the US.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.1%. Direxion Daily Financial Bull 3X Shares (FAS) was down 0.1%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.1% lower.Aegon (AEG) shares traded up 1% in early-hours activity after the company said it has increased its H2 share buyback program by 150 million euros ($174.9 million) to 350 million euros, effective Monday.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.01%, the Vanguard Industrials Index Fund (VIS) was down 0.1%, and the iShares US Industrials ETF (IYJ) rose 2%.United Airlines (UAL) stock was up more than 1% before the opening bell after CNBC reported Sunday that the air carrier is set to return to JFK airport through a partnership with JetBlue Airways (JBLU) as early as 2027. JetBlue stock also rose 1%.EnergyThe iShares US Energy ETF (IYE) was down 1%, while the State Street Energy Select Sector SPDR ETF (XLE) was 0.3% lower.Eni (E) stock was up more than 1% before market open, extending the previous session's loss. The Financial Times reported Monday that the company is expanding its investment in nuclear fusion, targeting a commercial fusion plant in Europe by the early 2040s or sooner.CommoditiesFront-month US West Texas Intermediate crude oil retreated by 1.7% to reach $85.55 per barrel on the New York Mercantile Exchange. Natural gas was up 1.5% at $2.82 per 1 million British Thermal Units. The United States Oil Fund (USO) decreased 1.3%, while the United States Natural Gas Fund (UNG) was 3.4% higher.Gold futures for November were up by 0.7% at $4,716.00 an ounce on the Comex. Silver futures gained 0.4% to reach $70.05 an ounce. SPDR Gold Shares (GLD) rose 1.1%, and the iShares Silver Trust (SLV) was 0.2% lower.

Dow JonesNasdaq CompositeS&P 500$AEG$BABA$BETH$BITO$E$EEM$EETH$EXI$FAS$FAZ$GLD$GSK$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$JBLU$PMR$PSN$QQQ$RTH$SLV$SOXX$SPY$UAL$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Asia Markets

European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading

European equities traded in the US as American depositary receipts started the week tracking modestly higher late Monday morning, rising 0.31% to 1,970.56 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical companies argenx (ARGX) and DBV Technologies (DBVT), which climbed 16% and 5.1% respectively. They were followed by telecommunications company Nokia (NOK) and biopharmaceutical company Cellectis (CLLS), which advanced 2.5% and 2% respectively.The decliners from continental Europe were led by medical device maker EDAP TMS (FOCL) and internet browser company Opera (OPRA), which dropped 4.6% and 2.7% respectively. They were followed by brewing company Anheuser-Busch InBev (BUD) and consumer goods company Unilever (UL), which lost 2.4% and 1.6% respectively.The gainers from the UK were led by biotech firm Autolus Therapeutics (AUTL) and biopharmaceutical company Akari Therapeutics (AKTX), which rose 6.3% and 2.8% respectively. They were followed by biopharmaceutical companies GSK (GSK) and Bicycle Therapeutics (BCYC), which were up 1.6% and 1.5% respectively.The decliners from the UK and Ireland were led by biopharmaceutical company Mereo BioPharma Group (MREO) and communications company WPP (WPP), which fell 5.4% and 3% respectively. They were followed by alcoholic beverage company Diageo (DEO) and biopharmaceutical company NuCana (NCNA), which decreased 2.6% and 2.5% respectively.

$AKTX$ARGX$AUTL$BCYC$BUD$CLLS$DBVT$DEO$FOCL$GSK$MREO$NCNA$NOK$OPRA$UL$WPP
Wire

Merck's Weekly HIV Treatment Pipeline 'Interesting,' UBS Says

Merck's (MRK) "HIV pipeline" is brewing in the background, as weekly treatment are interesting and showing path towards long-acting treatments, UBS Securities said in a report emailed Tuesday.The company presented phase 3 data showing its once-weekly oral combination of islatravir and lenacapavir was noninferior to Gilead Sciences' (GILD) biktarvy and other standard treatments. The firm expects Merck and Gilead Sciences to file data with the FDA soon, with a potential approval in 2027, according to the report.The firm viewed alimatravir as "intriguing" because its once-monthly dosing, fast onset and lack of a "loading dose" could appeal to patients seeking alternatives to daily PrEP. Phase 3 data are expected in 2027, potentially supporting a launch as early as 2028, the report said.Merck is also advancing a weekly combination of ulonivirine and islatravir into phase 3 testing. However, the firm said "adoption" could take time because of competition from Gilead and GSK (GSK) and the likelihood that the products will initially be used mainly as "switch" therapies, according to the report.UBS kept its buy rating on Merck with a price target of $145.Price: $128.79, Change: $+1.02, Percent Change: +0.79%

$GILD$GSK$MRK
Wire

GSK's ViiV Healthcare Highlights New Long-Acting Injectable Data on Cabenuva in HIV Treatment

GSK's (GSK) majority-owned ViiV Healthcare unit reported trial data that back Cabenuva's, also known as cabotegravir plus rilpivirine, potential as a long-acting injectable HIV treatment, according to a Wednesday statement.The LATA trial's week 96 results demonstrated Cabenuva's superiority over daily oral therapy in 476 virologically suppressed adolescents of ages 12 to 19 years with HIV in certain African countries, GSK said. Meanwhile, data from the US-based OPERA cohort showed that Cabenuva maintained virologic suppression comparable with daily oral therapy in 6,800 adults with HIV, GSK added.GSK also said six-month follow-up data from the phase 1 CLARITY trial supported a "more favorable" injection experience with long-acting cabotegravir, compared with lenacapavir, after a single dose.The company is also investigating an intramuscular formulation of cabotegravir dosed three times a year for HIV prevention, with data to be presented at a future medical event, according to the statement.Price: $53.05, Change: $-0.66, Percent Change: -1.24%

$GSK
Sectors

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 2.3% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.4%.The iShares Biotechnology ETF (IBB) was up 0.8%.In corporate news, Iqvia (IQV) shares surged 13% after it reported a year-over-year increase in Q2 adjusted earnings and revenue. The company also raised its 2026 outlook.GSK (GSK) shares advanced 3.3% after it posted higher Q2 core earnings and sales that also beat analysts' estimates. Separately, GSK licensor Hansoh's phase 3 trial of risvutatug rezetecan to treat osteosarcoma, the most common primary bone cancer, achieved its primary endpoint in progression-free survival, GSK said Tuesday.Seer (SEER) shareholders Bradley Radoff and Michael Torok said Tuesday they have submitted their fourth non-binding proposal to buy the company, raising their offer to $2.55 per share in cash. Seer shares jumped past 9%.Zimmer Biomet (ZBH) shares climbed 3.7% after UBS upgraded the stock to buy from sell, and raised the price target to $115 from $89.

$GSK$IQV$SEER$ZBH
Sectors

Sector Update: Healthcare Stocks Gain in Afternoon Trading

Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 2.2% and the State Street Health Care Select Sector SPDR ETF (XLV) rising 2.3%.The iShares Biotechnology ETF (IBB) was up 0.8%.In corporate news, GSK (GSK) shares gained 3.9% after the firm posted higher Q2 core earnings and sales that also beat analysts' estimates. Separately, GSK licensor Hansoh's phase 3 trial of risvutatug rezetecan to treat osteosarcoma, the most common primary bone cancer, achieved its primary endpoint in progression-free survival, GSK said Tuesday.Seer (SEER) shareholders Bradley Radoff and Michael Torok said Tuesday they have submitted their fourth non-binding proposal to buy the company, raising their offer to $2.55 per share in cash. Seer shares jumped past 5%.Iqvia (IQV) shares surged 12% after it reported higher Q2 adjusted earnings and revenue, and raised its 2026 outlook.

$GSK$IQV$SEER
Sectors

Sector Update: Healthcare

Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 2.2% and the State Street Health Care Select Sector SPDR ETF (XLV) rising 2.3%.The iShares Biotechnology ETF (IBB) was up 0.8%.In corporate news, GSK (GSK) shares gained 3.8% after it posted higher Q2 core earnings and sales that also beat analysts' estimates. Separately, GSK licensor Hansoh's phase 3 trial of risvutatug rezetecan to treat osteosarcoma, the most common primary bone cancer, achieved its primary endpoint in progression-free survival, GSK said Tuesday.

$GSK
Wire

GSK Licensor's Late-Stage China Study for Risvutatug Rezetecan in Bone Cancer Meets Primary Endpoint

GSK (GSK) licensor Hansoh's phase 3 trial of risvutatug rezetecan in osteosarcoma, the most common primary bone cancer, achieved its primary endpoint in progression-free survival, GSK said Tuesday.The trial, which was conducted in China in patients with osteosarcoma who have progressed or relapsed after receiving at least two prior lines of systemic therapy, showed that the therapy led to a statistically significant improvement in progression-free survival compared with chemotherapy, according to the statement.Hansoh also reported consistent benefit across secondary endpoints like overall survival, GSK added.Safety profile was consistent with previous findings in the same tumor type, with no new safety signals identified, the company said. Hansoh will use the trial data for regulatory submissions in China, GSK said.Price: $53.96, Change: $+1.98, Percent Change: +3.80%

$GSK
Asia Markets

European Equities Traded in US as ADRs Ease in Tuesday Trading

European equities traded in the US as American depositary receipts eased late Tuesday morning with the S&P Europe Select ADR Index down 0.1% to 1,903.66.From continental Europe, the gainers were led by consumer goods company Unilever (UL) and software firm SAP (SAP), which climbed 8.6% and 4.8%, respectively. They were followed by pharmaceutical company Sanofi (SNY) and brewing company Anheuser-Busch InBev (BUD), which advanced 3.7% and 3%, respectively.The decliners from continental Europe were led by telecommunications operator Nokia (NOK) and biopharmaceutical company DBV Technologies (DBVT), which dropped 6.3% and 5.1%, respectively. They were followed by medical device maker EDAP TMS (FOCL) and semiconductor company Sequans Communications (SQNS), which lost 3.3% and 3.1%, respectively.The gainers from the UK were led by biotech firm Trinity Biotech (TRIB) and software company Endava (DAVA), which rose 9.6% and 7.9%, respectively. They were followed by pharmaceutical company GSK (GSK) and communications company WPP (WPP), which were up 6.5% and 6.4%, respectively.The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics (SLN) and lender Barclays (BCS), which fell 7.8% and 7.3%, respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and lender Lloyds Banking Group (LYG), which dropped 7% and 2.5%, respectively.

$BCS$BDRX$BUD$DAVA$DBVT$FOCL$GSK$LYG$NOK$SAP$SLN$SNY$SQNS$TRIB$UL$WPP

Showing 1-20 of 57

Track with the FINWIRES app suite

FolioX
FolioX
Track GSK in your portfolio
WheelAI
WheelAI
Analyze GSK options with the wheel strategy
StockInsider
StockInsider
See market sentiment on GSK